Literature DB >> 15195499

Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome.

I Lombardi1, S Luisi, B Quirici, P Monteleone, F Bernardi, M Liut, E Casarosa, M Palumbo, F Petraglia, A R Genazzani.   

Abstract

Several studies have been performed during recent years to investigate the existence of a possible endocrine cause for premenstrual syndrome (PMS); the results reported are often discordant. Great interest has been raised around allopregnanolone, which could be involved in the determination of mood disorders reported by PMS patients. During the luteal phase, lower levels of this hormone have been detected in PMS patients. The aim of our study was to evaluate estradiol, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), androstenedione, total and free testosterone, cortisol, pregnenolone and allopregnanolone levels in 20 patients suffering from PMS and to compare them with those found in 20 fertile healthy women in the follicular and the luteal phases. Adrenocorticotropic hormone (ACTH) tests after dexamethasone suppression were performed in 10 patients of each group during the follicular and the luteal phases. In the PMS group, significantly lower allopregnolone levels were found in the luteal phase, while progesterone was lower in the PMS group in both phases. In the PMS group, higher free testosterone levels were found during the luteal phase and higher DHEA levels in both the follicular and the luteal phases. The present data confirm reduced allopregnanolone levels in the luteal phase in PMS patients, together with higher levels of DHEA and free testosterone. It is possible to conclude that, in addition to the previously described reduced luteal secretion of allopregnanolone, the adrenal gland production of this steroid in PMS sufferers is also impaired in the luteal phase. Considering the specific actions of these hormones on the control of mood and behavior, this specific hormonal milieu may contribute to the cyclic occurrence of anxiety, aggressiveness and irritability reported by PMS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195499     DOI: 10.1080/09513590310001652955

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  14 in total

1.  5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

Authors:  Pedro E Martinez; David R Rubinow; Lynnette K Nieman; Deloris E Koziol; A Leslie Morrow; Crystal E Schiller; Dahima Cintron; Karla D Thompson; Khursheed K Khine; Peter J Schmidt
Journal:  Neuropsychopharmacology       Date:  2013-08-14       Impact factor: 7.853

2.  Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder.

Authors:  Cynthia Neill Epperson; Brian Pittman; Kathryn Ann Czarkowski; Stephanie Stiklus; John Harrison Krystal; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2007-02-21       Impact factor: 7.853

Review 3.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

4.  ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist-induced hypogonadism and ovarian steroid replacement.

Authors:  Ellen E Lee; Lynnette K Nieman; Pedro E Martinez; Veronica L Harsh; David R Rubinow; Peter J Schmidt
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

Review 5.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

6.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

Review 7.  The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment.

Authors:  Constance Guille; Susan Spencer; Idil Cavus; C Neill Epperson
Journal:  Epilepsy Behav       Date:  2008-03-17       Impact factor: 2.937

Review 8.  Neurosteroids in the context of stress: implications for depressive disorders.

Authors:  Susan S Girdler; Rebecca Klatzkin
Journal:  Pharmacol Ther       Date:  2007-05-24       Impact factor: 12.310

Review 9.  Hypothalamic-pituitary-adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior.

Authors:  A Leslie Morrow; Patrizia Porcu; Kevin N Boyd; Kathleen A Grant
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

10.  The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.

Authors:  T V Nguyen; J M Reuter; N W Gaikwad; D M Rotroff; H R Kucera; A Motsinger-Reif; C P Smith; L K Nieman; D R Rubinow; R Kaddurah-Daouk; P J Schmidt
Journal:  Transl Psychiatry       Date:  2017-08-08       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.